Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

Abstract

Aims: The aim of this study was to describe the effectiveness of highly active antiretroviral treatment for HIV after the treatment became publicly available in Norway in August 1996 and through to the year 2000. The effectiveness was studied for the three main transmission groups for HIV in Norway. Methods: Effectiveness was measured as change in progression to AIDS after highly active antiretroviral treatment for HIV was introduced in the population of HIV-diagnosed persons. Notifications of HIV diagnosed persons and persons with AIDS from 1983 to 2000 in Norway were used in the analysis. Progression to AIDS after August 1996 compared with progression to AIDS before 1996 was analysed by Kaplan-Meier curves and Cox regression models. Results: Progression to AIDS slowed after highly active antiretroviral treatment was introduced. The intensity of getting AIDS was significantly reduced after August 1996 compared with the intensity of getting AIDS before August 1996. The reduction in intensity after August 1996 was less explicit in the two years following August 1996 than in the subsequent two and a half years from August 1998 to December 2000. The reduction was less explicit among HIV-diagnosed intravenous drug users. Conclusions: The effectiveness of highly active antiretroviral treatment lasted for at least four and a half years and increased after the first two calendar years. The problem of less effectiveness among HIV-diagnosed intravenous drug users should be addressed by the health authorities.

Keywords

AIDS highly active antiretroviral treatment (HAART)HIV heterosexual homosexual (MSM)intravenous drug user (IDU)survival analysis.

Get full access to this article

View all access options for this article.

References

Carrasco DA , Straten MV , Tyring SK A review of antiretroviral drugs. Dermatologic Therapy 2000; 13: 305 - 17.

Staszewski S. , Hill AM , Bartlett J. , Eron JJ , Katlama C. , Johnson J. , et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997; 11: 477 - 83.

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21.

Mouton Y. , Alfandari S. , Valette M. , Cartier F. , Dellamonica P. , Humbert G. , et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101 - F105.

Detels R. , Munoz A. , McFarlane G. , Kingsley LA , Margolick JB , Giorgi J. , et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-1503.

Egger M. , Hirschel B. , Francioli P. , Sudre P. , Wirz M. , Flepp M. , et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study . Br Med J 1997; 315: 1194 - 9.

Parpia T. , Raab GM , Goldberg DJ , Allardice GM , McMenamin J. , Whitelaw J. , et al. Effect of combination therapy on immunologic progression of human immunodeficiency virus at a population level. Am J Epidemiol 2001; 153: 898 - 902.

Hit HIV-1 hard, but only when necessary. Lancet 2000; 355: 2147 - 52.

Aavitsland P. , Nilsen Ø , Lystad A. Anonymous reporting of HIV infection: an evaluation of the HIV/AIDS surveillance system in Norway 1983-2000. Eur J Epidemiol 2000; 17: 479 - 89.

10.

Kaplan EL , Meier P. Non-parametric estimation from incomplete observations. Je Am Stat Assoc 1958; 53: 457 - 81: 562 - 3.

11.

Cox DR Regression models and life tables (with discussion). J Roy Stat Soc Series B 1972; 34: 187 - 220.

12.

Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355: 1131 - 7.

13.

Eskild A. , Magnus P. , Samuelsen SO , Sohlberg C. , Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993; 22: 315 - 20.